• Home
  • Company
    • Back
    • Company
    • Team
    • Corporate deck
    • History
    • Investors
  • Science
    • Back
    • Science
    • Publications
    • Collaborations
    • Differentiation
  • Clinical
    • Back
    • Clinical
    • Prostate Cancer
    • Haematology
    • Targeted Tumours
  • News
    • Back
    • News
    • Press releases
    • Blogs
  • Contact

Blogs

Short information articles

Our science and its application

  • Jan 27, 2022

    CCS1477 is now inobrodib: how a drug gets its name

  • Nov 19, 2021

    Demystifying cancer clinical trials for patients

  • Jan 14, 2021

    CCS1477 publishes in Cancer Discovery: a new strategy to treat cancer

  • Oct 27, 2020

    Patient focused pull; pioneering research push

  • Aug 6, 2020

    Flexible, expedient management of our clinical trials

  • Apr 16, 2020

    Targeting p300/CBP through to specific oncology applications

  • More press releases

  • Feb 20, 2020

    The discovery of CCS1477, first of its kind, p300/CBP inhibitor

  • Jan 15, 2020

    Targeting p300/CBP: a new approach to treating cancer

Applications of Inobrodib

  • Prostate Cancer Late stage, metastatic castrate-resistant prostate cancer (mCRPC)
  • Haematology Blood cancers including multiple myeloma, AML and lymphomas
  • Targeted Tumours Tumours with p300 or CBP mutations, or driven by AR or MYC

About CellCentric

CellCentric is a clinical stage biotech company focused on the development of a first of its kind, p300/CBP inhibitor to treat specific cancer types.

Quick links

  • Company
  • Team
  • Investors
  • Publications
  • Science
  • Clinical
  • Collaborations
  • Differentiation
  • Updates
  • Press releases
  • Contact

Follow us

Follow us and stay up to date with our latest news, events and scientific posters.

Follow us on Twitter

Copyright © 2022 Cellcentric

  • Contact us
Designed and built by Onespacemedia